Zhuhai Medefa Biotechnology Co., Ltd. is located in the Guangdong-Macao Deep Cooperation Zone in Hengqin, Guangdong Province. It was founded by several returned Austrian doctors. The founding shareholders responsible for the company's operation management have long-term management and innovation experience in multinational companies, and the core technical team Composed of the world's top R&D talents.

Medfa adopts cutting-edge synthetic biology engineering technology and focuses on independent innovation and development of a new generation of fully bio-based naturally degradable PHA biomaterials and the large-scale production, application and marketization of its downstream high-end derivative products.Since its establishment in early 2019, the company has made a comprehensive layout in terms of intellectual property rights, and has achieved patent coverage of the entire industrial chain of new PHA materials from strains, fermentation processes, purification, and application development, and continues to deepen its layout and establish a PHA material application technology platform.

Medefa Adhering to the business purpose of leading technology, its PHA industrial-grade production line and large-scale preparation technology of medical PHA materials and healthy active small molecule beta acid have entered the world's advanced ranks.In view of the fact that PHA materials are fully bio-based and can be naturally degraded in all natural environments, they are becoming green, low-carbon and environmentally friendly materials with broad market prospects; in view of the excellent biocompatibility and processability of Medfa medical PHA materials, It is also gaining more and more applications in the field of innovative disposable/absorbable medical devices; as a high-end downstream derivative of PHA, beta acid health active small molecules are also gaining high-intensity use because of their special effects on brain health. Widely favored by the brain crowd.

Since its establishment, Medefa has won relevant honors such as National High-tech Enterprise, Provincial Specialized and New Small and Medium-sized Enterprises, Guangdong Provincial Biosynthetic Engineering Technology Research Center, and Postdoctoral Workstation, and has received tens of millions of yuan in special funds from the local provincial and municipal governments. and over 100 million yuan in industrial funds and venture capital support.After several years of severe challenges caused by the epidemic, the company is now developing rapidly and is committed to becoming the world's leading supplier of new bio-based PHA material solutions and contributing to building a green China, a healthy China, and global sustainable development.